Sun Pharmaceutical Industries, India’s largest drugmaker, is preparing to make a massive $12 billion bid to acquire US-based pharmaceutical company Organon & Co.. If the deal is successful, it will become the biggest overseas acquisition ever made by an Indian pharma company.
The deal is currently in its final stages. Sun Pharma has already spent more than three months conducting detailed checks and analysis of Organon’s business. The company is now working on arranging funds and is expected to submit a final offer soon. Major global banks such as JPMorgan, Citi, MUFG, and Standard Chartered are likely to support the financing, showing that the deal is being taken very seriously.
Sun Pharma’s interest in Organon is part of its long-term strategy to expand globally, especially in the United States. Organon focuses on areas like women’s health, biosimilars, and established branded medicines. By acquiring Organon, Sun Pharma aims to strengthen its presence in these segments and reduce its dependence on low-margin generic drugs. The company has been gradually shifting its focus towards specialty and innovative medicines, which offer better profits and long-term growth.
This acquisition could mark a major turning point for Sun Pharma. It would significantly increase its global reach and product portfolio, helping it compete with some of the world’s biggest pharmaceutical companies. Experts believe that if the deal goes through, it could transform Sun Pharma into a more innovation-driven and globally competitive company.
However, the deal also comes with certain risks. Organon currently carries a high debt of around $8 billion, which could become a financial burden after the acquisition. There are also concerns about how smoothly such a large company can be integrated into Sun Pharma’s existing operations. These worries have already affected investor sentiment, with Sun Pharma’s shares falling by around 4% after news of the potential deal came out.
Another challenge is competition. Reports suggest that other global investors and private equity firms are also interested in acquiring Organon. This means that Sun Pharma may face strong competition, and the final outcome is still uncertain.
In conclusion, Sun Pharma’s planned $12 billion bid for Organon is a bold and ambitious move that could reshape the company’s future. While it offers strong growth opportunities and global expansion, it also carries financial and operational risks. The coming weeks will be crucial in determining whether this historic deal becomes a reality.